Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2023 · 10-Q
Revenue$5.13M$5.13M−7.4% vs Q2 2022 Net Income-$21.39M-$21.39MN/M vs Q2 2022 EPS Diluted-$0.02-$0.02N/M vs Q2 2022 Operating Income-$44,908,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$44,978,000N/M Margins · derivedOperating margin-875.4%−85.4 pt vs Q2 2022
Net margin-416.9%+387.0 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end